Cipla reported INR69.77B in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Arca Biopharma USD 31.78M 8.81M Sep/2026
aTyr Pharma USD 16.46M 5.07M Sep/2026
Bio Path USD 9.15M 468K Mar/2026
Brainstorm Cell Therapeutics USD 12.38M 621K Jun/2026
Capricor Therapeutics USD 29.9M 3.07M Sep/2026
Cara Therapeutics USD 8.08M 3.18M Sep/2026
Cipla INR 69.77B 366.6M Sep/2026
Dr.Reddys Laboratories INR 154.3B 3.04B Sep/2026
Immunic USD 31.55M 290K Sep/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sun Pharmaceuticals INR 235.92B 9.7B Sep/2026
TherapeuticsMD USD 5.82M 655K Jun/2024
UPL INR 450.45B 102.97B Sep/2026